None

Survey: Only 61% of healthcare payers say they will be ready for ICD-10

Many third-party payers believe they won't meet the 2014 deadline for ICD-10 compliance, a new study shows. That could be a problem for your practice.

Survey: 61% of healthcare payers say they won't be ready for ICD-10

Many third-party payers believe they won't meet the 2014 deadline for ICD-10 compliance, a new study shows. That could be a problem for your practice.

Payers ink deal to help CMS build primary care initiative for physicians

Forty-five insurers have committed to supporting an innovative payment initiative in seven states. Find out which payers are participating and what tradeoffs 75 practices had to make.

Show us the money: US payers demand value

It's not enough to show that a new drug works in order to secure reimbursement by US health care payers; increasingly biotechnology and pharmaceutical companies must demonstrate that their products al...

In the Eye of the Storm: Payer Value Perspective Key to Market Access

Précis:  Rita E. Numerof, Ph.D delves into the topic of market access, offering a detailed study on how best to approach, and work with, payers....

Health Outcomes Liaisons and Payers Talk Health Economics

The burden of proving drugs’ cost-effectiveness data falls in part to health outcomes liaisons (HOLs) who work between pharmaceutical companies and payers to get their company’s drugs onto formula...

Medicare Part B ranks above commercial payers in new MGMA study

Medicare Part B was rated highest among payers by providers for overall satisfaction, according to the newest version of an annual study from MGMA-ACMPA.

How to Make the Payers Pay: Join the Xconomy Event April 9

How will your company convince payers that they should pay for that new health innovation you’ve been developing for years? Do you have the data to prove your drug or device is worth the price you p...

Use of economic evaluation in decision making: evidence and recommendations for improvement.

Information about the value for money of a medicine as derived from an economic evaluation can be used for decision-making purposes by policy makers, healthcare payers, healthcare professionals and ph...

The emergence of diagnostic imaging technologies in breast cancer: discovery, regulatory approval, reimbursement, and adoption in clinical guidelines.

In this article, we trace the chronology of developments in breast imaging technologies that are used for diagnosis and staging of breast cancer, including mammography, ultrasonography, magnetic reson...

Effect of source of funding on weight loss up to 3 years after gastric banding.

BACKGROUND: Laparoscopic adjustable gastric banding (LAGB) is a popular choice for patients seeking weight loss surgery. Since behavioural change appears to play a role in weight loss outcomes we post...

Subgroup analyses of clinical effectiveness to support health technology assessments.

Subgroup analysis is an integral part of access and reimbursement dossiers, in particular health technology assessment (HTA), and their HTA recommendations are often limited to subpopulations. HTA rec...

Clinical and economic challenges facing pharmacogenomics.

In this paper, we examine the clinical and economic challenges that face developers of and payers for personalized drugs and companion diagnostics. We review and summarize clinical, regulatory and rei...